Clinical Trials Logo

Onychomycosis clinical trials

View clinical trials related to Onychomycosis.

Filter by:

NCT ID: NCT06417983 Not yet recruiting - Fungal Infection Clinical Trials

Topical Application of Essential Oils to Treat Onchomycosis

NailFungus
Start date: May 30, 2024
Phase:
Study type: Observational

Patients with documented onychomycosis of one or more toe nails will be treated with a daily application of a topical lacquer containing several essential oils.

NCT ID: NCT06327295 Not yet recruiting - Onychomycosis Clinical Trials

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

Start date: March 30, 2024
Phase: Phase 2
Study type: Interventional

The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis

NCT ID: NCT06254027 Not yet recruiting - Onychomycosis Clinical Trials

Clinical Investigation for the Evaluation of Efficacy and Safety of Two Medical Devices for Onychomycosis Treatment

Start date: March 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness of FORTE, ACTIVE COVER LIGHT and Loceryl® in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface compared to baseline.

NCT ID: NCT06175013 Not yet recruiting - Onychomycosis Clinical Trials

Evaluation of a Combination of Two Medical Devices and One Device Use in the Treatment of Toenail Onychomycosis

Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this clinical investigation is to evaluate the efficacy of the tested products in medium to moderate onychomycosis after 112 days of treatments. The main question it aims to answer is the effectiveness of the use of a combination of two investigational devices (Sérum PURIFIANT + Sérum BOOSTER) on the percentage of healthy nail surface after 112 days of treatment. Participants will apply one or two devices on the affected toenail during the study. - Patients included on the groupe 1 will use Sérum PURIFIANT only, twice daily. - Patient included on group 2 will use Sérum PURIFIANT, twice daily associated with Sérum BOOSTER twice weekly. For this investigation, 44 patients (22 patients per group) presenting at least one infected toenail will be included to reach this objective.

NCT ID: NCT06074315 Recruiting - Onychomycosis Clinical Trials

Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This is a Pre-IDE, prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study to evaluate safety and effectiveness of Nail Genesis DLSO Product for the treatment of DLSO compared with vehicle in infected great toenails in a total of 338 males and non-pregnant, non-lactating, females between 18 and 65 years of age (inclusive). Subjects will be randomized in a 2:1 ratio to receive either Nail Genesis DLSO Product or vehicle. Subject eligibility will be determined during a Screening assessment. Subjects will complete a 4week washout period after discontinuation of a topical product or a 12-month washout period after discontinuation of an oral product or light-based therapy prior to randomization. Eligible subjects will be randomized in a 2:1 ratio to receive Nail Genesis DLSO Product or vehicle, respectively. During the 52-week trial, study medication will be administered once daily to the target toenail for 48 weeks. A subject will be considered to have completed the study when he or she has completed the study assessments at Week 52. The 52-week visit is for follow-up safety assessments.

NCT ID: NCT06036654 Recruiting - Hyperthermia Clinical Trials

Infrared Bioeffect System for the Treatment of Onychomycosis

Start date: February 24, 2023
Phase: N/A
Study type: Interventional

Onychomycosis is a common nail plate infection caused by dermatophytes, non-dermatophytic molds, and yeasts. The disease is difficult to achieve self-healing and predisposed to secondary bacterial infections. There are currently multiple medications that can be used for the treatment of onychomycosis. The limitations are high recurrence rate and high cost, time-consuming and drug interactions. Several FDA approved laser devices have been available for the treatment of onychomycosis since 2010. As an emerging physical therapy modality, laser and light have advantages including extensive applicable range, simple operation, less trauma, and it will not lead to generation of new resistant strains. Therefore, it has been popularized and applied in clinics, especially among elderly, immunocompromised patients, or those with liver and kidney dysfunction. Laser systems in the near-infrared spectrum (780 nm∼ 3,000 nm wavelength), which are commonly used in onychomycosis, exert their effect by direct heating of target tissues, but it can cause unbearable physical pain to the patient. Compared with laser, controllable infrared bioeffect system has the advantages of high safety, less trauma, and less pain. Reported in the literature, it has been observed that regression of distant, untreated skin lesions in patients treated locally with controllable infrared bioeffect system, especially in inflammatory skin diseases such as viral warts and sporotrichosis. The aim of the research is to evaluate the safety and efficacy of controllable infrared bioeffect system in treatment of onychomycosis.

NCT ID: NCT06006455 Recruiting - Clinical trials for Onychomycosis of Toenail

Effect of the Erchonia® LunulaLaserâ„¢ for the Treatment of Toenail Onychomycosis

Start date: June 15, 2020
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to demonstrate the efficacy of the Erchonia LunulaLaserâ„¢, for the treatment of onychomycosis of the toenail.

NCT ID: NCT05999474 Recruiting - Clinical trials for Onychomycosis of Fingernail

Combined Fractional CO2 Laser With Topical Tioconazole Versus Q-switched Nd:YAG Laser in the Treatment of Onychomycosis; a Randomized Controlled Trial

Start date: September 1, 2022
Phase: Phase 4
Study type: Interventional

Our aim is to assess the clinical efficacy and the safety of fractional CO2 laser combined with topical tioconazole versus Q-switched Nd:YAG laser in the treatment of OM.

NCT ID: NCT05809297 Not yet recruiting - Onychomycosis Clinical Trials

Diode Laser and Photodynamic Therapy Vs. Ciclopirox.

Laser
Start date: September 1, 2023
Phase: Phase 4
Study type: Interventional

The main objective of this study is to compare the efficacy of treatment of onychomycosis by: diode laser combined with photodynamic therapy, and topical treatment with Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer. The study is a low-intervention, randomised controlled clinical trial. Patient recruitment will be done by including in the sample those patients who have diagnostic confirmation of onychomycosis in the Chiropodology and Surgery Service of the University Podiatry Clinic of the Complutense University of Madrid. Participants in the trial will be assigned with equal probability to each treatment arm, according to their consecutive inclusion in the study. Subsequently, treatment assignment will be determined by a random code. The treatment used will be evident to both the participant and the podiatrist responsible for the intervention. Visits will be made every 7 days at the start of treatment and for 9 weeks in group 1 (treatment with laser and photodynamic therapy), and monthly visits in group 2 (treatment with ciclopirox nail polish) during the 12 months of follow-up. Regardless of the follow-up week at which healing occurs, all patients will be reviewed at 3, 6, 9 and 12 months after the first visit.

NCT ID: NCT05674747 Recruiting - Clinical trials for Onychomycosis of Toenail

Pilot Study of Swift Microwave Device for Onychomycosis

Start date: March 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open, single site, pilot study in Canadian subjects diagnosed with mild to moderate toenail onychomycosis caused by dermatophytes. Three microwave treatment frequencies will be compared for efficacy and safety, evaluated by frequency of treatment-related adverse events, clinical improvement of a treated target toenail and inactivation/elimination of fungus in the target toenail. Outcomes will be evaluated at Month 6, Month 9 and Month 12 after initiation of treatments. Subjects not achieving 'temporary increase in clear nail' at Month 6 may receive extra microwave treatments to Month 9 or Month 12 to improve outcomes.